UroGen Pharma Ltd. (NASDAQ:URGN) Given Average Rating of “Buy” by Brokerages
UroGen Pharma Ltd. (NASDAQ:URGN – Get Free Report) has received an average rating of “Buy” from the six brokerages that are presently covering the company, Marketbeat Ratings reports. Five analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. The average 12-month price objective among […]
More Stories
Hiroshi Nishijima Acquires 32,052 Shares of Zoomcar Holdings, Inc. (NASDAQ:ZCAR) Stock
Zoomcar Holdings, Inc. (NASDAQ:ZCAR – Get Free Report) CEO Hiroshi Nishijima bought 32,052 shares of the company’s stock in a...
SunLink Health Systems (NYSE:SSY) Coverage Initiated by Analysts at StockNews.com
StockNews.com initiated coverage on shares of SunLink Health Systems (NYSE:SSY – Free Report) in a research report report published on...
Andean Precious Metals Corp. (CVE:APM) Senior Officer Juan Carlos Sandoval Amare Purchases 31,300 Shares
Andean Precious Metals Corp. (CVE:APM – Get Free Report) Senior Officer Juan Carlos Sandoval Amare acquired 31,300 shares of the...
PHX Minerals (NYSE:PHX) Now Covered by StockNews.com
StockNews.com assumed coverage on shares of PHX Minerals (NYSE:PHX – Free Report) in a research report report published on Sunday....
Insider Selling: Bandwidth Inc. (NASDAQ:BAND) CFO Sells 1,305 Shares of Stock
Bandwidth Inc. (NASDAQ:BAND – Get Free Report) CFO Daryl Raiford sold 1,305 shares of Bandwidth stock in a transaction dated...
Stardust Power (NASDAQ:SDST) versus Alumina (OTCMKTS:AWCMY) Critical Contrast
Alumina (OTCMKTS:AWCMY – Get Free Report) and Stardust Power (NASDAQ:SDST – Get Free Report) are both basic materials companies, but...